Profile data is unavailable for this security.
About the company
Sonova Holding AG is a Switzerland-based company operating in the healthcare sector. The Company, along with its subsidiaries, designs, develops, manufactures, distributes and services hearing systems for adults and children with hearing impairment. The Company is active in two operating segments: the Hearing instruments segment includes the companies that are active in the design, development, manufacture, distribution and service of hearing instruments and related products, and the Cochlear implants segment includes the companies that are active in the design, development, manufacture, distribution and service of hearing implants and related products. It operates worldwide and distributes its products in over 90 countries through its own distribution network and through independent distributors. Sonova Holding AG is the holding company of the Sonova Group and operates the wholly owned subsidiaries Comfort Audio GmbH and Hansaton Akustik GmbH.
- Revenue in CHF (TTM)3.71bn
- Net income in CHF564.70m
- Incorporated1985
- Employees18.55k
- LocationSonova Holding AGLaubisruetistrasse 28STAEFA 8712SwitzerlandCHE
- Phone+41 589283333
- Fax+41 589283345
- Websitehttps://www.sonova.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Smith & Nephew plc | 4.99bn | 269.71m | 9.56bn | 18.00k | 35.40 | 2.08 | 11.21 | 1.92 | 0.2761 | 0.2761 | 5.11 | 4.71 | 0.5535 | 0.7128 | 4.30 | 241,711.30 | 2.99 | 4.10 | 3.62 | 4.99 | 69.04 | 71.27 | 5.41 | 8.02 | 1.11 | 5.48 | 0.4125 | 79.59 | 6.40 | 2.50 | 17.94 | -16.88 | 4.24 | 1.85 |
| BioMerieux SA | 3.55bn | 383.45m | 10.76bn | 14.65k | 28.16 | 2.97 | 16.36 | 3.03 | 3.46 | 3.46 | 32.04 | 32.80 | 0.7356 | 1.82 | 5.63 | 259,811.60 | 7.71 | 9.30 | 9.57 | 12.31 | 55.72 | 56.51 | 10.48 | 12.38 | 1.20 | 236.14 | 0.1258 | 17.76 | 2.39 | 8.70 | -20.95 | 6.87 | 8.36 | 19.42 |
| Sartorius AG | 3.10bn | 77.57m | 13.15bn | 13.76k | 139.94 | 4.39 | 27.10 | 4.24 | 1.22 | 1.22 | 48.66 | 38.73 | 0.3365 | 1.84 | 9.34 | 227,432.60 | 1.37 | 8.21 | 1.73 | 11.83 | 43.95 | 50.93 | 4.06 | 14.15 | 1.13 | 2.41 | 0.545 | 19.59 | -18.66 | 16.74 | -69.74 | 7.74 | 19.14 | 3.66 |
| Sartorius Stedim Biotech SA | 2.56bn | 157.74m | 15.25bn | 10.38k | 93.82 | 4.21 | 35.81 | 5.95 | 1.79 | 1.79 | 29.22 | 39.95 | 0.4145 | 1.75 | 8.84 | 257,644.00 | 2.61 | 11.87 | 3.04 | 15.12 | 41.82 | 50.96 | 6.31 | 17.44 | 1.03 | 2.95 | 0.4266 | 18.73 | -20.53 | 18.02 | -64.65 | 8.28 | 21.82 | 3.90 |
| Straumann Holding AG | 2.47bn | 307.19m | 17.59bn | 11.15k | 57.26 | 8.94 | 39.37 | 7.13 | 1.93 | 1.70 | 15.47 | 12.34 | 0.715 | 1.76 | 4.21 | 222,176.90 | 8.95 | 10.68 | 11.84 | 13.63 | 72.76 | 74.95 | 12.52 | 15.15 | 1.55 | 13.15 | 0.187 | 37.50 | 3.92 | 12.08 | -43.40 | -2.04 | 11.54 | 10.12 |
| Sonova Holding AG | 3.71bn | 564.70m | 18.09bn | 18.55k | 32.17 | 7.90 | 22.15 | 4.88 | 9.43 | 9.43 | 61.94 | 38.43 | 0.6838 | 2.33 | 6.84 | 204,236.70 | 10.54 | 10.87 | 13.40 | 13.88 | 72.42 | 71.97 | 15.42 | 17.77 | 0.823 | 21.70 | 0.419 | 35.21 | -2.98 | 5.59 | -5.84 | 5.77 | 1.75 | 8.20 |
| Koninklijke Philips NV | 16.82bn | -437.25m | 21.82bn | 69.28k | -- | -- | 33.25 | 1.30 | -0.4847 | -0.335 | 19.14 | -- | -- | -- | -- | 258,972.70 | -- | 0.3678 | -- | 0.5013 | 42.18 | 43.84 | -2.59 | 0.6049 | -- | 5.35 | -- | -- | 1.92 | 0.0529 | 71.87 | -- | -5.24 | -- |
| Coloplast A/S | 3.38bn | 631.38m | 23.14bn | 16.25k | 38.96 | 11.06 | 29.20 | 6.85 | 22.61 | 22.61 | 121.01 | 79.62 | 0.5618 | 2.44 | 6.01 | 1,663,692.00 | 10.50 | 16.21 | 14.49 | 22.91 | 67.59 | 67.85 | 18.69 | 21.02 | 0.6637 | 8.49 | 0.5578 | 92.23 | 10.33 | 8.54 | 5.62 | 5.46 | 14.30 | 5.29 |
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price International Ltd.as of 15 Oct 2024 | 3.03m | 5.08% |
| Capital International Ltd.as of 10 Sep 2024 | 1.99m | 3.34% |
| MFS Institutional Advisors, Inc.as of 31 Mar 2024 | 1.85m | 3.10% |
| UBS Asset Management Switzerland AGas of 31 Mar 2024 | 1.83m | 3.06% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 1.68m | 2.82% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 1.23m | 2.06% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 966.54k | 1.62% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 913.00k | 1.53% |
| BlackRock Advisors (UK) Ltd.as of 08 Nov 2024 | 726.16k | 1.22% |
| MFS International (UK) Ltd.as of 30 Sep 2024 | 714.19k | 1.20% |
